

Reporte de caso: Enfermedad de Wilson, un reto diagnóstico.

Nombre de los estudiantes

Jaime Navarro Navarro

Trabajo de Investigación o Tesis Doctoral como requisito para optar el título de
Magíster en genética

Tutores

Dayan Lozano Solano

Cristiano Trindade

RESUMEN

Antecedentes: La enfermedad de Wilson es un trastorno genético de transmisión autosómica recesiva, producida por la mutación del gen ATP7B. Es considerada una enfermedad rara o huérfana debido a su baja prevalencia. Sin embargo, es una enfermedad crónica que puede llevar al deterioro de la calidad de vida del paciente poniéndolo en riesgo de muerte, por lo que se considera una enfermedad catastrófica. El gen ATP7B es determinante en el proceso de eliminación del cobre del organismo, por tanto, la mutación génica implica a su acumulación principalmente en el hígado y Sistema Nervioso Central (SNC). El diagnóstico de la enfermedad en etapas tempranas es vital para el control de los síntomas y evitar el deterioro hepático, neurológico y/o psiquiátrico del paciente. Sin embargo, la inespecificidad de los síntomas, así como la tardía edad de inicio de estos, dificulta su diagnóstico oportuno. La detección de los signos clínicos de la enfermedad y las anomalías genéticas asociadas, son necesarias para iniciar un tratamiento efectivo, si bien la enfermedad no es curable, el tratamiento farmacológico oportuno con medicamentos quelantes, minimizan los efectos del cobre en el organismo.

Objetivos: Determinar las características clínicas y el genotipo y de un paciente con diagnóstico clínico de la enfermedad de Wilson y analizar su evolución durante el tratamiento recibido.

Materiales y Métodos: Estudio de caso. Se describieron las características clínicas y genéticas del individuo con diagnóstico presuntivo de enfermedad de Wilson (WD). Se realizó el análisis genético de las variantes presentadas por el paciente mediante secuenciación genómica y otras pruebas de química sanguínea para relacionar los signos y síntomas con la variante presentada por el paciente. La investigación tuvo la aprobación ético-científica del comité de ética investigación de la Universidad Simón Bolívar de Barranquilla, Colombia. Fue acorde con los requisitos de no maleficencia, beneficencia y autonomía y

establecidos en las normas vigentes sobre investigación en seres humanos, contempladas en la Declaración de Helsinki de la Asociación Médica Mundial y la Resolución 8430 de 1993 del Ministerio de Salud de Colombia.

Resultados: La edad de aparición de la enfermedad en el paciente estudiado es de 25 años. El paciente presentó manifestaciones psiquiátricas, neurológicas y hepáticas; acompañado de signos característicos de la enfermedad de Wilson: Ceruloplasmina baja, Cobre sérico disminuido y Cobre en orina aumentado y anillo de Kayser, el cual debido a la buena adherencia al tratamiento ha desaparecido. El paciente presentó dos mutaciones asociadas con la enfermedad de Wilson de acuerdo con la literatura: Transversión de una base T por una G (M [A T G]> R [A G G]) en heterocigosis cercana al sitio dador del splicing del intrón 13 (c.3060+5G>T) y deleción de una base C (c.3402delC) generando una alteración en el marco de lectura dando lugar a un codón de parada prematuro (p.Ala1135Glnfs*13).

Conclusiones: En la actualidad, el paciente se encuentra en aceptables condiciones generales a pesar de los notables efectos de invalidez que provoca la enfermedad de Wilson en las personas afectadas. Se considera que la satisfactoria evolución del sujeto está asociada a una buena adherencia al tratamiento, a la intervención multidisciplinaria y al incondicional apoyo psicosocial recibido por su núcleo familiar

Palabras clave: Enfermedades huérfanas, ATPasas Transportadoras de Cobre, Genotipo, Enfermedad de Wilson, Proteína ATP7A

ABSTRACT

Background: Wilson's disease is an autosomal recessive genetic transmission disorder, caused by the mutation of the ATP7B gene. It is considered a rare or orphan disease due to its low prevalence. However, it is a chronic disease that can lead to the deterioration of the patient's quality of life putting him at risk of death, which is why it is considered a catastrophic disease. The ATP7B gene is decisive in the process of eliminating copper from the body, therefore, gene mutation leads to its accumulation mainly in the liver and Central Nervous System (CNS). The diagnosis of the disease in early stages is vital for the control of the symptoms and to avoid the hepatic, neurological and / or psychiatric deterioration of the patient. However, the non-specificity of the symptoms, as well as the late age of onset of these, hinders their timely diagnosis. The detection of the clinical signs of the disease and the associated genetic abnormalities, are necessary to initiate an effective treatment, although the disease is not curable, the timely pharmacological treatment with chelating drugs minimizes the effects of copper in the organism

Objective: To determine the clinical characteristics and genotype and of a patient with a clinical diagnosis of Wilson's disease and analyze its evolution during the treatment received, for the disclosure of a clinical case, in order to generate timely diagnostic guidelines in these patients

Materials and Methods: The genetic analysis of the variants presented by the patient was performed by genomic sequencing and other blood chemistry tests to relate the signs and symptoms with the variant presented by the patient

Results: The age of onset of the disease in the patient studied is 25 years. The patient presented psychiatric, neurological and hepatic manifestations; accompanied by characteristic signs of Wilson's disease: Low ceruloplasmin, decreased serum copper and Increased urine copper and Kayser's ring, which due to good adherence to treatment has disappeared. The patient presented two mutations associated with Wilson's disease according to the literature: Transversion of a T base by a G (M [ATG]> R [AGG]) in heterozygosis close to the intron splicing donor site 13 (c. 3060 + 5G> T) and deletion of a C base (c.3402delC) generating an alteration in the reading frame resulting in a premature stop codon (e.g. Ala1135Glnfs * 13).

Conclusions:

At present, the patient is in acceptable general conditions despite the notable effects of disability caused by Wilson's disease in affected people. The satisfactory evolution of the subject is associated with good adherence to treatment, multidisciplinary intervention and unconditional psychosocial support received by their family nucleus.

KeyWords: Orphan diseases, copper absorption, genotype, Wilson's disease, ATP7B gene.

REFERENCIAS

1. Guerra Montero L, Ortega Álvarez F, Sumire Umeres J, Cok García J. Enfermedad de Wilson: forma hepática . [Internet]. Vol. 35, Revista de Gastroenterología del Perú . 2015. p. 361-5. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292015000400012
2. Foruny Olcina JR, Boixeda de Miquel D. Enfermedad de Wilson. Rev Española Enfermedades Dig [Internet]. 2010;102:53-4. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010000100009&nrm=iso
3. Millán Jiménez A, Ruiz Moreno M. Enfermedad de Wilson. En: Ergón, editor. Protocolos diagnóstico-terapéuticos de Gastroenterología, Hepatología y Nutrición Pediátrica. 2012.
4. Stenson PD, Mort M, Ball E V., Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet [Internet]. 2017;136(6):665-77. Disponible en: <http://link.springer.com/10.1007/s00439-017-1779-6>
5. Coffey AJ, Durkie M, Hague S, McLay K, Emmerson J, Lo C, et al. A genetic study of Wilson's disease in the United Kingdom. Brain [Internet]. mayo de 2013;136(5):1476-87. Disponible en: <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awt035>
6. Ministerio de Salud y Protección social. Resolución 2048 [Internet]. Bogotá; 2015. Disponible en: https://www.minsalud.gov.co/Normatividad_Nuevo/Resolución_2048_de_2015.pdf

7. Ministerio de Salud y Protección social. Ley 1392 [Internet]. Bogotá; 2010. Disponible en: <https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-1392-de-2010.pdf>
8. Ministerio de Salud y Protección social. Decreto 1954 [Internet]. Bogotá; 2012. Disponible en: <https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/Decreto-1954-de-2012.PDF>
9. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. *Lancet Neurol* [Internet]. 2015;14(1):103-13. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1474442214701905>
10. Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing . *Hum Genet* [Internet]. 2006;120(2):151-9. Disponible en: <http://link.springer.com/10.1007/s00439-006-0202-5>
11. Dzieżyc K, Karliński M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. *Eur J Neurol* [Internet]. 2014;21(2):332-7. Disponible en: <http://doi.wiley.com/10.1111/ene.12320>
12. EASL Clinical Practice Guidelines: Wilson's disease. *J Hepatol* [Internet]. marzo de 2012;56(3):671-85. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0168827811008129>
13. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: An update . *Hepatology* [Internet]. 2008;47(6):2089-111. Disponible en: <http://doi.wiley.com/10.1002/hep.22261>
14. Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, et al. Wilson's Disease in Children. *J Pediatr Gastroenterol Nutr* [Internet]. 2018;66(2):334-44. Disponible en: <http://insights.ovid.com/crossref?an=00005176-201802000-00032>
15. Broussolle E, Trocello J-M, Woimant F, Lachaux A, Quinn N. Samuel Alexander Kinnier Wilson. Wilson's disease, Queen Square and neurology . *Rev Neurol (Paris)* [Internet]. 2013;169(12):927-35. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0035378713008916>
16. Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease . *Nat Rev Dis Prim* [Internet]. 2018;4(1):21. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/30190489>
17. Barbosa ER, Machado AAC, Cançado ELR, Deguti MM, Scaff M. Wilson's Disease: a case report and a historical review . *Arq Neuropsiquiatr* [Internet]. 2009;67(2b):539-43. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2009000300036&lng=en&tlng=en
18. López Hernández M, Serrano Rufino M. Enfermedad de Wilson: reporte de un caso y revisión de la literatura. *Med interna México* [Internet]. 2007;23(5):458-63. Disponible en: <https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=18434>

19. Walshe JM. History of Wilson disease. En 2017. p. 1-5. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/B978044463625600001X>
20. Ferenci P. Guías de Práctica Clínica de la EASL: Enfermedad de Wilson. J Hepatol [Internet]. 2011;56:671–685. Disponible en: https://easl.eu/wp-content/uploads/2018/10/2012-Wilson_ES.pdf
21. Clark Feoktistova Y. Enfermedad de Wilson. Actualidad del tema [Internet]. Vol. 38, Revista Médica Electrónica. 2016. p. 57-66. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242016000100006&nrm=iso
22. Saito T. An assessment of efficiency in potential screening for Wilson's disease . J Epidemiol Community Heal [Internet]. 1981;35(4):274-80. Disponible en: <http://jech.bmj.com/cgi/doi/10.1136/jech.35.4.274>
23. Bachmann H, Lössner J, Biesold D. Wilson's disease in the German Democratic Republic. I. Genetics and epidemiology . Z Gesamte Inn Med [Internet]. 1979;34(24):744-8. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/549306>
24. Xie J-J, Wu Z-Y. Wilson's Disease in China . Neurosci Bull [Internet]. 2017;33(3):323-30. Disponible en: <http://link.springer.com/10.1007/s12264-017-0107-4>
25. Lo C, Bandmann O. Epidemiology and introduction to the clinical presentation of Wilson disease. En 2017. p. 7-17. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/B9780444636256000021>
26. Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease . Nat Rev Dis Prim [Internet]. 2018;4(1):21. Disponible en: <http://www.nature.com/articles/s41572-018-0018-3>
27. Svetel M, Pekmezović T, Petrović I, Tomić A, Kresojević N, Ješić R, et al. Long-term outcome in Serbian patients with Wilson disease . Eur J Neurol [Internet]. 2009;16(7):852-7. Disponible en: <http://doi.wiley.com/10.1111/j.1468-1331.2009.02607.x>
28. Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R, et al. Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort . Clin Gastroenterol Hepatol [Internet]. 2014;12(4):683-9. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1542356513014304>
29. Cumings JN. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration . Brain [Internet]. 1948;71(Pt. 4):410-5. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/18124738>
30. Gomes A, Dedoussis G V. Geographic distribution of ATP7B mutations in Wilson disease . Ann Hum Biol [Internet]. 2016;43(1):1-8. Disponible en: <http://www.tandfonline.com/doi/full/10.3109/03014460.2015.1051492>
31. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide . Nat Med [Internet]. 2007;13(2):164-70. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/17259995>
32. Letelier ME, Sánchez-Jofré S, Peredo-Silva L, Cortés-Troncoso J, Aracena-Parks P. Mechanisms underlying iron and copper ions toxicity in

- biological systems: Pro-oxidant activity and protein-binding effects . *Chem Biol Interact* [Internet]. 2010;188(1):220-7. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0009279710003959>
33. Mufti AR, Burstein E, Csomos RA, Graf PCF, Wilkinson JC, Dick RD, et al. XIAP Is a Copper Binding Protein Deregulated in Wilson's Disease and Other Copper Toxicosis Disorders . *Mol Cell* [Internet]. 2006;21(6):775-85. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1097276506000815>
34. Huster D, Finegold MJ, Morgan CT, Burkhead JL, Nixon R, Vanderwerf SM, et al. Consequences of Copper Accumulation in the Livers of the Atp7b^{-/-} (Wilson Disease Gene) Knockout Mice . *Am J Pathol* [Internet]. 2006;168(2):423-34. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0002944010621037>
35. Ma J, Betts NM. Zinc and Copper Intakes and Their Major Food Sources for Older Adults in the 1994–96 Continuing Survey of Food Intakes by Individuals (CSFII) . *J Nutr* [Internet]. 2000;130(11):2838-43. Disponible en: <https://academic.oup.com/jn/article/130/11/2838/4686136>
36. Russell K, Gillanders LK, Orr DW, Plank LD. Dietary copper restriction in Wilson's disease. *Eur J Clin Nutr* [Internet]. 2018;72(3):326-31. Disponible en: <https://doi.org/10.1038/s41430-017-0002-0>
37. Maryon EB, Molloy SA, Kaplan JH. Cellular glutathione plays a key role in copper uptake mediated by human copper transporter 1 . *Am J Physiol Physiol* [Internet]. 2013;304(8):C768-79. Disponible en: <http://www.physiology.org/doi/10.1152/ajpcell.00417.2012>
38. Llanos RM, Michalczyk AA, Freestone DJ, Currie S, Linder MC, Ackland ML, et al. Copper transport during lactation in transgenic mice expressing the human ATP7A protein . *Biochem Biophys Res Commun* [Internet]. 2008;372(4):613-7. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0006291X08009881>
39. Hatori Y, Yan Y, Schmidt K, Furukawa E, Hasan NM, Yang N, et al. Neuronal differentiation is associated with a redox-regulated increase of copper flow to the secretory pathway . *Nat Commun* [Internet]. 2016;7(1):10640. Disponible en: <http://www.nature.com/articles/ncomms10640>
40. Baker ZN, Cobine PA, Leary SC. The mitochondrion: a central architect of copper homeostasis. *Metallomics* [Internet]. 2017;9(11):1501-12. Disponible en: <http://xlink.rsc.org/?DOI=C7MT00221A>
41. Xiao Z, Brose J, Schimo S, Ackland SM, La Fontaine S, Wedd AG. Unification of the copper(I) binding affinities of the metallo-chaperones Atx1, Atox1, and related proteins: detection probes and affinity standards . *J Biol Chem* [Internet]. 2011;286(13):11047-55. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/21258123>
42. Liggi M, Murgia D, Civolani A, Demelia E, Sorbello O, Demelia L. The relationship between copper and steatosis in Wilson's disease . *Clin Res Hepatol Gastroenterol* [Internet]. 2013;37(1):36-40. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S2210740112001192>
43. Muchenditsi A, Yang H, Hamilton JP, Koganti L, Housseau F, Aronov L, et al. Targeted inactivation of copper transporter Atp7b in hepatocytes

- causes liver steatosis and obesity in mice . *Am J Physiol Liver Physiol* [Internet]. 2017;313(1):G39-49. Disponible en: <http://www.physiology.org/doi/10.1152/ajpgi.00312.2016>
44. Zhang H, Yan C, Yang Z, Zhang W, Niu Y, Li X, et al. Alterations of serum trace elements in patients with type 2 diabetes . *J Trace Elem Med Biol* [Internet]. 2017;40:91-6. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0946672X16302462>
45. Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-Schönauer U, Steindl-Munda P, et al. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome . *J Trace Elem Med Biol* [Internet]. 2017;39:100-7. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0946672X16302218>
46. Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A, et al. A Role for Low Hepatic Copper Concentrations in Nonalcoholic Fatty Liver Disease . *Am J Gastroenterol* [Internet]. 2010;105(9):1978-85. Disponible en: <http://insights.ovid.com/crossref?an=00000434-201009000-00013>
47. Pierson H, Muchenditsi A, Kim B-E, Ralle M, Zachos N, Huster D, et al. The Function of ATPase Copper Transporter ATP7B in Intestine . *Gastroenterology* [Internet]. 2018;154(1):168-180.e5. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0016508517361784>
48. Das A, Sudhahar V, Chen G-F, Kim HW, Youn S-W, Finney L, et al. Endothelial Antioxidant-1: a Key Mediator of Copper-dependent Wound Healing in vivo . *Sci Rep* [Internet]. 2016;6(1):33783. Disponible en: <http://www.nature.com/articles/srep33783>
49. Jurevics H, Hostettler J, Muse ED, Sammond DW, Matsushima GK, Toews AD, et al. Cerebroside synthesis as a measure of the rate of remyelination following cuprizone-induced demyelination in brain . *J Neurochem* [Internet]. 2001;77(4):1067-76. Disponible en: <http://doi.wiley.com/10.1046/j.1471-4159.2001.00310.x>
50. Urso E, Maffia M. Behind the Link between Copper and Angiogenesis: Established Mechanisms and an Overview on the Role of Vascular Copper Transport Systems . *J Vasc Res* [Internet]. 2015;52(3):172-96. Disponible en: <https://www.karger.com/Article/FullText/438485>
51. Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, et al. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse . *Ann Oncol* [Internet]. 2013;24(6):1491-8. Disponible en: <https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mds654>
52. Mounajjed T, Oxentenko AS, Qureshi H, Smyrk TC. Revisiting the Topic of Histochemically Detectable Copper in Various Liver Diseases With Special Focus on Venous Outflow Impairment . *Am J Clin Pathol* [Internet]. 2013;139(1):79-86. Disponible en: <https://academic.oup.com/ajcp/article/139/1/79/1766367>
53. Huster D. Structural and metabolic changes in Atp7b -/- mouse liver and potential for new interventions in Wilson's disease . *Ann N Y Acad Sci*

- [Internet]. 2014;1315(1):37-44. Disponible en: <http://doi.wiley.com/10.1111/nyas.12337>
54. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide . *Nat Med* [Internet]. 2007;13(2):164-70. Disponible en: <http://www.nature.com/articles/nm1539>
 55. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease . *Gastroenterology* [Internet]. 1968;55(3):354-67. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/5675366>
 56. Walshe JM, Potter G. The pattern of the whole body distribution of radioactive copper (⁶⁷Cu, ⁶⁴Cu) in Wilson's Disease and various control groups . *Q J Med* [Internet]. 1977;46(184):445-62. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/413153>
 57. Mikol J, Vital C, Wassef M, Chappuis P, Poupon J, Lecharpentier M, et al. Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases . *Acta Neuropathol* [Internet]. 2005;110(5):451-8. Disponible en: <http://link.springer.com/10.1007/s00401-005-1061-1>
 58. Horoupian DS, Sternlieb I, Scheinberg IH. Neuropathological findings in penicillamine-treated patients with Wilson's disease . *Clin Neuropathol* [Internet]. 7(2):62-7. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/3390974>
 59. Scheiber IF, Dringen R. Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes . *Neurosci Lett* [Internet]. 2011;498(1):42-6. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0304394011005428>
 60. Meenakshi-Sundaram S, Mahadevan A, Taly AB, Arunodaya GR, Swamy HS, Shankar SK. Wilson's disease: a clinico-neuropathological autopsy study . *J Clin Neurosci* [Internet]. 2008;15(4):409-17. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/18242093>
 61. Dusek P, Bahn E, Litwin T, Jabłonka-Salach K, Łuciuk A, Huelnhagen T, et al. Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study . *Neuropathol Appl Neurobiol* [Internet]. 2017;43(6):514-32. Disponible en: <http://doi.wiley.com/10.1111/nan.12341>
 62. Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson's disease . *Mov Disord* [Internet]. 2001;16(4):719-23. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/11481698>
 63. Iwański S, Seniów J, Leśniak M, Litwin T, Członkowska A. Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilson's disease . *Neuropsychology* [Internet]. 2015;29(1):25-30. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/24885450>
 64. Südmeyer M, Pollok B, Hefter H, Gross J, Butz M, Wojtecki L, et al. Synchronized brain network underlying postural tremor in Wilson's disease . *Mov Disord* [Internet]. 2006;21(11):1935-40. Disponible en: <http://doi.wiley.com/10.1002/mds.21104>
 65. Prashanth LK, Sinha S, Taly AB, A.Mahadevan, Vasudev MK, Shankar SK. Spectrum of epilepsy in Wilson's disease with

- electroencephalographic, MR imaging and pathological correlates . J Neurol Sci [Internet]. 2010;291(1-2):44-51. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0022510X10000158>
66. Langwińska-Wośko E, Litwin T, Dzieżyc K, Karlinski M, Członkowska A. Optical coherence tomography as a marker of neurodegeneration in patients with Wilson's disease . Acta Neurol Belg [Internet]. 2017;117(4):867-71. Disponible en: <http://link.springer.com/10.1007/s13760-017-0788-5>
67. Langwińska-Wośko E, Litwin T, Szulborski K, Członkowska A. Optical coherence tomography and electrophysiology of retinal and visual pathways in Wilson's disease . Metab Brain Dis [Internet]. 2016;31(2):405-15. Disponible en: <http://link.springer.com/10.1007/s11011-015-9776-8>
68. Miranda M, Venegas P. El anillo de Kayser-Fleischer como signo diagnóstico en la Enfermedad de Wilson . Rev Chil Neuropsiquiatr [Internet]. 2002;40(2). Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-92272002000200005&lng=en&nrm=iso&tlng=en
69. Sullivan CA. Dense Kayser-Fleischer ring in asymptomatic Wilson's disease (hepatolenticular degeneration). Br J Ophthalmol [Internet]. 2002;86(1):114-114. Disponible en: <http://bjo.bmj.com/cgi/doi/10.1136/bjo.86.1.114>
70. Padilla Galindo H, Serrano A, Polo A, García R, Acosta Reyes J, Navarro-Jiménez E. Caracterización clínica-epidemiológica de las glomerulonefritis primarias un centro de referencia de caribe colombiano, en niños menores de 15 años, de enero 2008 a diciembre 2013. Rev Colomb Nefrol [Internet]. 2014;1. Disponible en: <http://www.revistanefrologia.org/index.php/rcn/article/view/152>
71. Aroca-Martínez G, González-Torres HJ, Domínguez-Vargas A, Fontalvo-Pastorizo J, Silva-Díaz D, Cadena-Bonfanti A. Respuesta a la farmacoterapia en pacientes con glomerulonefritis membranoproliferativa en una clínica de Barranquilla, Colombia. 2007-2014. Rev la Fac Med [Internet]. 1 de julio de 2018;66(3):301-5. Disponible en: <https://revistas.unal.edu.co/index.php/revfacmed/article/view/63178>
72. Castillo Parodi L, Navarro Jiménez, Eduardo Arango Quiroz Y, López Avendaño, Anderson Mejía Varela V, González Torres, Henry J Aroca Martínez G. Asociación de obesidad con la Enfermedad Renal Crónica de pacientes atendidos en la Clínica de la Costa. 2005-2014. Rev Colomb Nefrol [Internet]. 2016;3(1). Disponible en: <http://www.revistanefrologia.org/index.php/rcn/article/view/217>
73. Walshe JM. The acute haemolytic syndrome in Wilson's disease--a review of 22 patients. QJM [Internet]. 2013;106(11):1003-8. Disponible en: <https://academic.oup.com/qjmed/article-lookup/doi/10.1093/qjmed/hct137>
74. Forman SJ, Kumar KS, Redeker AG, Hochstein P. Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms . Am J Hematol [Internet]. 1980;9(3):269-75. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/7234865>

75. Benders AA, Li J, Lock RA, Bindels RJ, Bonga SE, Veerkamp JH. Copper toxicity in cultured human skeletal muscle cells: the involvement of Na⁺/K⁺-ATPase and the Na⁺/Ca²⁺-exchanger . *Pflugers Arch* [Internet]. 1994;428(5-6):461-7. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/7838667>
76. Hogland HC, Goldstein NP. Hematologic (cytopenic) manifestations of Wilson's disease (hepatolenticular degeneration) . *Mayo Clin Proc* [Internet]. 1978;53(8):498-500. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/682676>
77. Dzieżyc K, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson disease . *Handb Clin Neurol* [Internet]. 2017;142:157-69. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/28433099>
78. Zhuang X-H, Mo Y, Jiang X-Y, Chen S-M. Analysis of renal impairment in children with Wilson's disease . *World J Pediatr* [Internet]. 2008;4(2):102-5. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/18661763>
79. Weiss KH, Van de Moortele M, Gotthardt DN, Pfeiffenberger J, Seeßle J, Ullrich E, et al. Bone demineralisation in a large cohort of Wilson disease patients . *J Inherit Metab Dis* [Internet]. 2015;38(5):949-56. Disponible en: <http://doi.wiley.com/10.1007/s10545-015-9815-y>
80. Menerey KA, Eider W, Brewer GJ, Braunstein EM, Schumacher HR, Fox IH. The arthropathy of Wilson's disease: clinical and pathologic features. *J Rheumatol* [Internet]. 1988;15(2):331-7. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/3361541>
81. Buksińska-Lisik M, Litwin T, Pasierski T, Członkowska A. Cardiac assessment in Wilson's disease patients based on electrocardiography and echocardiography examination. *Arch Med Sci* [Internet]. 2019;15(4):857-64. Disponible en: <https://www.termedia.pl/doi/10.5114/aoms.2017.69728>
82. Lewis D, Pilankatta R, Inesi G, Bartolommei G, Moncelli MR, Tadini-Buoninsegni F. Distinctive Features of Catalytic and Transport Mechanisms in Mammalian Sarco-endoplasmic Reticulum Ca²⁺ ATPase (SERCA) and Cu⁺ (ATP7A/B) ATPases. *J Biol Chem* [Internet]. 2012;287(39):32717-27. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.M112.373472>
83. Pilankatta R, Lewis D, Inesi G. Involvement of Protein Kinase D in Expression and Trafficking of ATP7B (Copper ATPase) . *J Biol Chem* [Internet]. 2011;286(9):7389-96. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.M110.171454>
84. Hatori Y, Hirata A, Toyoshima C, Lewis D, Pilankatta R, Inesi G. Intermediate Phosphorylation Reactions in the Mechanism of ATP Utilization by the Copper ATPase (CopA) of *Thermotoga maritima* . *J Biol Chem* [Internet]. 2008;283(33):22541-9. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.M802735200>
85. Inesi G, Pilankatta R, Tadini-Buoninsegni F. Biochemical characterization of P-type copper ATPases. *Biochem J* [Internet]. 2014;463(2):167-76. Disponible en: <https://portlandpress.com/biochemj/article/463/2/167/48328/Biochemical-characterization-of-Ptype-copper>

86. Kaplan JH, Lutsenko S. Copper Transport in Mammalian Cells: Special Care for a Metal with Special Needs. *J Biol Chem* [Internet]. 2009;284(38):25461-5. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.R109.031286>
87. González-Guerrero M, Hong D, Argüello JM. Chaperone-mediated Cu + Delivery to Cu + Transport ATPases. *J Biol Chem* [Internet]. 2009;284(31):20804-11. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.M109.016329>
88. La Fontaine S, Mercer JFB. Trafficking of the copper-ATPases, ATP7A and ATP7B: Role in copper homeostasis . *Arch Biochem Biophys* [Internet]. 2007;463(2):149-67. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S000398610700210X>
89. Argüello JM, Eren E, González-Guerrero M. The structure and function of heavy metal transport P1B-ATPases . *BioMetals* [Internet]. 2007;20(3-4):233-48. Disponible en: <http://link.springer.com/10.1007/s10534-006-9055-6>
90. Argüello JM. Identification of Ion-Selectivity Determinants in Heavy-Metal Transport P 1B -type ATPases. *J Membr Biol* [Internet]. 2003;195(2):93-108. Disponible en: <http://link.springer.com/10.1007/s00232-003-2048-2>
91. Arnesano F. Metallochaperones and Metal-Transporting ATPases: A Comparative Analysis of Sequences and Structures . *Genome Res* [Internet]. 2002;12(2):255-71. Disponible en: <http://www.genome.org/cgi/doi/10.1101/gr.196802>
92. Labes A, Schönheit P. Unusual Starch Degradation Pathway via Cyclodextrins in the Hyperthermophilic Sulfate-Reducing Archaeon *Archaeoglobus fulgidus* Strain 7324 . *J Bacteriol* [Internet]. 2007;189(24):8901-13. Disponible en: <http://jb.asm.org/cgi/doi/10.1128/JB.01136-07>
93. Harris ED. Cellular Copper Transport and Metabolism . *Annu Rev Nutr* [Internet]. 2000;20(1):291-310. Disponible en: <http://www.annualreviews.org/doi/10.1146/annurev.nutr.20.1.291>
94. Sitthisak S, Kittit T, Boonyonying K, Wozniak D, Mongkolsuk S, Jayaswal RK. McsA and the roles of metal-binding motif in *Staphylococcus aureus* . *FEMS Microbiol Lett* [Internet]. 2012;327(2):126-33. Disponible en: <https://academic.oup.com/femsle/article-lookup/doi/10.1111/j.1574-6968.2011.02468.x>
95. Wu C-C, Rice WJ, Stokes DL. Structure of a Copper Pump Suggests a Regulatory Role for Its Metal-Binding Domain . *Structure* [Internet]. 2008;16(6):976-85. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0969212608001512>
96. Tsuda T, Toyoshima C. Nucleotide recognition by CopA, a Cu+-transporting P-type ATPase . *EMBO J* [Internet]. 2009;28(12):1782-91. Disponible en: <http://emboj.embopress.org/cgi/doi/10.1038/emboj.2009.143>
97. Sazinsky MH, Agarwal S, Argüello JM, Rosenzweig AC. Structure of the Actuator Domain from the *Archaeoglobus fulgidus* Cu + -ATPase . *Biochemistry* [Internet]. 2006;45(33):9949-55. Disponible en: <https://pubs.acs.org/doi/10.1021/bi0610045>

98. Wu C-C, Allen GS, Stokes DL. Structure of CopA from *Archaeoglobus Fulgidus* by Cryoelectron Microscopy . *Biophys J* [Internet]. 2010;98(3):168a. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S000634950902712X>
99. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase . *Nat Genet* [Internet]. 1993;3(1):7-13. Disponible en: <http://www.nature.com/articles/ng0193-7>
100. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, Gilliam TC. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions . *Hum Mol Genet* [Internet]. 1994;3(9):1647-56. Disponible en: <https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/3.9.1647>
101. La Fontaine S, Mercer JFB. Trafficking of the copper-ATPases, ATP7A and ATP7B: Role in copper homeostasis . *Arch Biochem Biophys* [Internet]. 2007;463(2):149-67. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S000398610700210X>
102. Gourdon P, Sitsel O, Karlsen JL, Møller LB, Nissen P. Structural models of the human copper P-type ATPases ATP7A and ATP7B. *Biol Chem* [Internet]. 2012;393(4):205-16. Disponible en: <http://www.degruyter.com/view/j/bchm.2012.393.issue-4/hsz-2011-0249/hsz-2011-0249.xml>
103. Badenas C. Utilidad del estudio genético en el diagnóstico e intervención familiar en la enfermedad de Wilson . En: *Enfermedad de Wilson* [Internet]. Barcelona; 2015. Disponible en: <http://aeeh.es/wp-content/uploads/2015/12/1.-Celia-Badenas.pdf>
104. Human Gene Mutation Database. The Human Gene Mutation Database (HGMD) [Internet]. Disponible en: <http://www.hgmd.org>
105. The Universal Mutation Database. The ATP7B mutations database [Internet]. Disponible en: <http://www.umd.be/ATP7B/>
106. University of Alberta. Wilson Disease Mutation Database [Internet]. Disponible en: <http://www.wilsondisease.med.ualberta.ca/>
107. Firneisz G, Lakatos PL, Szalay F, Polli C, Glant TT, Ferenci P. Common mutations of ATP7B in Wilson disease patients from Hungary. *Am J Med Genet* [Internet]. 2002;108(1):23-8. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/11857545>
108. de Bie P, van de Sluis B, Burstein E, van de Berghe PVE, Muller P, Berger R, et al. Distinct Wilson's Disease Mutations in ATP7B Are Associated With Enhanced Binding to COMMD1 and Reduced Stability of ATP7B . *Gastroenterology* [Internet]. 2007;133(4):1316-26. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S001650850701400X>
109. Huster D, Kühne A, Bhattacharjee A, Raines L, Jantsch V, Noe J, et al. Diverse Functional Properties of Wilson Disease ATP7B Variants . *Gastroenterology* [Internet]. 2012;142(4):947-956.e5. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0016508512000169>

110. Ferenci P, Roberts EA. Defining Wilson Disease Phenotypes: From the Patient to the Bench and Back Again . *Gastroenterology* [Internet]. 2012;142(4):692-6. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0016508512002491>
111. Merle U, Weiss KH, Eisenbach C, Tuma S, Ferenci P, Stremmel W. Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease . *BMC Gastroenterol* [Internet]. 2010;10(1):8. Disponible en: <https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-10-8>
112. Okada T, Shiono Y, Kaneko Y, Miwa K, Hasatani K, Hayashi Y, et al. High prevalence of fulminant hepatic failure among patients with mutant alleles for truncation of ATP7B in Wilson's disease . *Scand J Gastroenterol* [Internet]. 2010;45(10):1232-7. Disponible en: <http://www.tandfonline.com/doi/full/10.3109/00365521.2010.492527>
113. Usta J, Wehbeh A, Rida K, El-Rifai O, Estiphan TA, Majarian T, et al. Phenotype-Genotype Correlation in Wilson Disease in a Large Lebanese Family: Association of c.2299insC with Hepatic and of p. Ala1003Thr with Neurologic Phenotype . Dmitriev OY, editor. *PLoS One* [Internet]. 2014;9(11):e109727. Disponible en: <https://dx.plos.org/10.1371/journal.pone.0109727>
114. Cocos R, Şendroi A, Schipor S, Bohîlţea LC, Şendroi I, Raicu F. Genotype-Phenotype Correlations in a Mountain Population Community with High Prevalence of Wilson's Disease: Genetic and Clinical Homogeneity . Dermaut B, editor. *PLoS One* [Internet]. 2014;9(6):e98520. Disponible en: <https://dx.plos.org/10.1371/journal.pone.0098520>
115. Mukherjee S, Dutta S, Majumdar S, Biswas T, Jaiswal P, Sengupta M, et al. Genetic defects in Indian Wilson disease patients and genotype–phenotype correlation . *Parkinsonism Relat Disord* [Internet]. 2014;20(1):75-81. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1353802013003519>
116. Frydman M, Bonne-Tamir B, Farrer LA, Conneally PM, Magazanik A, Ashbel S, et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus . *Proc Natl Acad Sci* [Internet]. 1985;82(6):1819-21. Disponible en: <http://www.pnas.org/cgi/doi/10.1073/pnas.82.6.1819>
117. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene . *Nat Genet* [Internet]. 1993;5(4):327-37. Disponible en: <http://www.nature.com/articles/ng1293-327>
118. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease . *Biochem Biophys Res Commun* [Internet]. 1993;197(1):271-7. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/8250934>
119. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, Gilliam TC. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions . *Hum Mol Genet* [Internet]. septiembre de

- 1994;3(9):1647-56. Disponible en:
<http://www.ncbi.nlm.nih.gov/pubmed/7833924>
120. Fanni D, Pilloni L, Orrù S, Coni P, Liguori C, Serra S, et al. Expression of ATP7B in normal human liver . Eur J Histochem [Internet]. 49(4):371-8. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/16377579>
121. Gupta A, Chattopadhyay I, Dey S, Nasipuri P, Das SK, Gangopadhyay PK, et al. Molecular Pathogenesis of Wilson Disease Among Indians: A Perspective on Mutation Spectrum in ATP7B gene, Prevalent Defects, Clinical Heterogeneity and Implication Towards Diagnosis . Cell Mol Neurobiol [Internet]. 2007;27(8):1023-33. Disponible en: <http://link.springer.com/10.1007/s10571-007-9192-7>
122. Ferenci P, Czlonkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, et al. Late-onset Wilson's disease . Gastroenterology [Internet]. 2007;132(4):1294-8. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/17433323>
123. Aggarwal A, Chandhok G, Todorov T, Parekh S, Tilve S, Zibert A, et al. Wilson disease mutation pattern with genotype-phenotype correlations from Western India: confirmation of p.C271* as a common Indian mutation and identification of 14 novel mutations . Ann Hum Genet [Internet]. 2013;77(4):299-307. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/23551039>
124. Gupta A, Aikath D, Neogi R, Datta S, Basu K, Maity B, et al. Molecular pathogenesis of Wilson disease: haplotype analysis, detection of prevalent mutations and genotype-phenotype correlation in Indian patients . Hum Genet [Internet]. 2005;118(1):49-57. Disponible en: <http://link.springer.com/10.1007/s00439-005-0007-y>
125. Kumar S, Thapa B, Kaur G, Prasad R. Analysis of most common mutations R778G, R778L, R778W, I1102T and H1069Q in Indian Wilson disease patients: correlation between genotype/phenotype/copper ATPase activity . Mol Cell Biochem [Internet]. 2007;294(1-2):1-10. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/17160357>
126. Santhosh S, Shaji R V, Eapen CE, Jayanthi V, Malathi S, Chandy M, et al. ATP7B mutations in families in a predominantly Southern Indian cohort of Wilson's disease patients . Indian J Gastroenterol [Internet]. 25(6):277-82. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/17264425>
127. Okada T, Shiono Y, Hayashi H, Satoh H, Sawada T, Suzuki A, et al. Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson's disease . Hum Mutat [Internet]. 2000;15(5):454-62. Disponible en: <http://doi.wiley.com/10.1002/%28SICI%291098-1004%28200005%2915%3A5%3C454%3A%3AAID-HUMU7%3E3.0.CO%3B2-J>
128. Al Jumah M, Majumdar R, Al Rajeh S, Awada A, Al Zaben A, Al Traif I, et al. A clinical and genetic study of 56 Saudi Wilson disease patients: identification of Saudi-specific mutations . Eur J Neurol [Internet]. 2004;11(2):121-4. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/14748773>

129. Stättermayer AF, Traussnigg S, Dienes H-P, Aigner E, Stauber R, Lackner K, et al. Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations . *J Hepatol* [Internet]. 2015;63(1):156-63. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0168827815000719>
130. Pingitore P, Pirazzi C, Mancina RM, Motta BM, Indiveri C, Pujia A, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function . *Biochim Biophys Acta - Mol Cell Biol Lipids* [Internet]. 2014;1841(4):574-80. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1388198113002795>
131. Schiefermeier M. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease . *Brain* [Internet]. 2000;123(3):585-90. Disponible en: <https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/123.3.585>
132. Litwin T, Gromadzka G, Członkowska A. Apolipoprotein E gene (APOE) genotype in Wilson's disease: Impact on clinical presentation . *Parkinsonism Relat Disord* [Internet]. 2012;18(4):367-9. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1353802011004305>
133. Stuehler B, Reichert J, Stremmel W, Schaefer M. Analysis of the human homologue of the canine copper toxicosis gene MURR1 in Wilson disease patients . *J Mol Med* [Internet]. 2004;82(9). Disponible en: <http://link.springer.com/10.1007/s00109-004-0557-9>
134. Lovicu M, Dessì V, Lepori MB, Zappu A, Zancan L, Giacchino R, et al. The canine copper toxicosis gene MURR1 is not implicated in the pathogenesis of Wilson disease. *J Gastroenterol* [Internet]. 24 de julio de 2006;41(6):582-7. Disponible en: <http://link.springer.com/10.1007/s00535-006-1807-0>
135. Wu Z-Y, Zhao G-X, Chen W-J, Wang N, Wan B, Lin M-T, et al. Mutation analysis of 218 Chinese patients with Wilson disease revealed no correlation between the canine copper toxicosis gene MURR1 and Wilson disease . *J Mol Med* [Internet]. 2006;84(5):438-42. Disponible en: <http://link.springer.com/10.1007/s00109-005-0036-y>
136. Simon I, Schaefer M, Reichert J, Stremmel W. Analysis of the human Atox 1 homologue in Wilson patients . *World J Gastroenterol* [Internet]. 2008;14(15):2383. Disponible en: <http://www.wjgnet.com/1007-9327/full/v14/i15/2383.htm>
137. Lee BH, Kim JH, Lee SY, Jin HY, Kim K-J, Lee J-J, et al. Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort . *Liver Int* [Internet]. 2011;31(6):831-9. Disponible en: <http://doi.wiley.com/10.1111/j.1478-3231.2011.02503.x>
138. Bost M, Piguet-Lacroix G, Parant F, Wilson CMR. Molecular analysis of Wilson patients: Direct sequencing and MLPA analysis in the ATP7B gene and Atox1 and COMMD1 gene analysis . *J Trace Elem Med Biol* [Internet]. 2012;26(2-3):97-101. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0946672X12000806>

139. Senzolo M, Loreno M, Fagioli S, Zanús G, Canova D, Masier A, et al. Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins . Clin Neurol Neurosurg [Internet]. 2007;109(1):71-5. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0303846706000126>
140. Kegley KM, Sellers MA, Ferber MJ, Johnson MW, Joelson DW, Shrestha R. Fulminant Wilson's Disease Requiring Liver Transplantation in One Monozygotic Twin Despite Identical Genetic Mutation . Am J Transplant [Internet]. 2010;10(5):1325-9. Disponible en: <http://doi.wiley.com/10.1111/j.1600-6143.2010.03071.x>
141. Członkowska A, Gromadzka G, Chabik G. Monozygotic female twins discordant for phenotype of Wilson's disease. Mov Disord [Internet]. 2009;24(7):1066-9. Disponible en: <http://doi.wiley.com/10.1002/mds.22474>
142. Bethin KE, Cimato TR, Ettinger MJ. Copper Binding to Mouse Liver S-Adenosylhomocysteine Hydrolase and the Effects of Copper on Its Levels . J Biol Chem [Internet]. 1995;270(35):20703-11. Disponible en: <http://www.jbc.org/lookup/doi/10.1074/jbc.270.35.20703>
143. Delgado M, Pérez-Miguelsanz J, Garrido F, Rodríguez-Tarduchy G, Pérez-Sala D, Pajares MA. Early effects of copper accumulation on methionine metabolism . Cell Mol Life Sci [Internet]. 2008;65(13):2080-90. Disponible en: <http://link.springer.com/10.1007/s00018-008-8201-4>
144. Medici V, Shibata NM, Kharbanda KK, LaSalle JM, Woods R, Liu S, et al. Wilson's disease: Changes in methionine metabolism and inflammation affect global DNA methylation in early liver disease . Hepatology [Internet]. 2013;57(2):555-65. Disponible en: <http://doi.wiley.com/10.1002/hep.26047>
145. Medici V, Shibata NM, Kharbanda KK, Islam MS, Keen CL, Kim K, et al. Maternal choline modifies fetal liver copper, gene expression, DNA methylation, and neonatal growth in the tx-j mouse model of Wilson disease . Epigenetics [Internet]. 2014;9(2):286-96. Disponible en: <http://www.tandfonline.com/doi/abs/10.4161/epi.27110>
146. Bem RS de, Raskin S, Muzzillo DA, Deguti MM, Cancado ELR, Araujo TF, et al. Wilson's disease in Southern Brazil: genotype-phenotype correlation and description of two novel mutations in ATP7B gene . Arq Neuropsiquiatr [Internet]. 2013;71(8):503-7. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000800503&lng=en&tlng=en
147. Machado AAC, Deguti MM, Genschel J, Cançado ELR, Bochow B, Schmidt H, et al. Neurological manifestations and ATP7B mutations in Wilson's disease . Parkinsonism Relat Disord [Internet]. 2008;14(3):246-9. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S135380200700171X>
148. Gupta S. Cell therapy to remove excess copper in Wilson's disease . Ann N Y Acad Sci [Internet]. 2014;1315(1):70-80. Disponible en: <http://doi.wiley.com/10.1111/nyas.12450>
149. Ministerio de Salud y Protección Social de Colombia. Resolución 8430 de 1993. Colombia; 1993 p. 12.

150. Asociación Médica Mundial. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. 1964 p. 6.
151. Nagel J, Miralles S. Enfermedad de Wilson: comienzo con síntomas psiquiátricos. Hallazgos en resonancia magnética encefálica . Rev Argentina Radiol [Internet]. 2007;71(3):267-71. Disponible en: <https://www.redalyc.org/articulo.oa?id=382538453004>
152. Pulido JN, Alfonso L, Medina ADC, Guillermo J, Tamayo S, Medina JCR. Enfermedad de Wilson. Acta Médica Colomb [Internet]. 2002; Disponible en: <http://actamedicacolombiana.com/anexo/articulos/03-2002-09.htm>
153. Ha-Hao D, Hefter H, Stremmel W, Castañeda-Guillot C, Hernández AH, Cox DW, et al. His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. Eur J Hum Genet [Internet]. 1998;6(6):616-23. Disponible en: <http://www.nature.com/articles/5200237>
154. Whisstock JC, Lesk AM. Prediction of protein function from protein sequence and structure . Q Rev Biophys [Internet]. 2003;36(3):307-40. Disponible en: https://www.cambridge.org/core/product/identifier/S0033583503003901/type/journal_article
155. Margarit E, Bach V, Gómez D, Bruguera M, Jara P, Queralt R, et al. Mutation analysis of Wilson disease in the Spanish population - identification of a prevalent substitution and eight novel mutations in the ATP7B gene . Clin Genet [Internet]. 2005;68(1):61-8. Disponible en: <http://doi.wiley.com/10.1111/j.1399-0004.2005.00439.x>
156. Brage A, Tomé S, García A, Carracedo Á, Salas A. Clinical and molecular characterization of Wilson disease in Spanish patients . Hepatol Res [Internet]. 2007;37(1):18-26. Disponible en: <http://doi.wiley.com/10.1111/j.1872-034X.2007.00010.x>
157. Arnab Gupta, Svetlana Lutsenko. Evolution of Copper Transporting ATPases in Eukaryotic Organisms . Curr Genomics [Internet]. 2012;13(2):124-33. Disponible en: <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-2029&volume=13&issue=2&spage=124>
158. Príncipe Felipe. Genetics and Genomics of Neuromuscular and Neurodegenerative Diseases . [Internet]. Disponible en: http://espinos.cipf.es/images/articulos/ATP7B_Tabla_Mutaciones.pdf
159. Paradisi I, De Freitas L, Arias S. Most frequent mutation c.3402delC (p.Ala1135GlnfsX13) among Wilson disease patients in Venezuela has a wide distribution and two old origins . Eur J Med Genet [Internet]. 2015;58(2):59-65. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1769721214002195>
160. Loudianos G, Dessì V, Lovicu M, Angius A, Kanavakis E, Tzetis M, et al. Haplotype and mutation analysis in Greek patients with Wilson disease . Eur J Hum Genet [Internet]. 1998;6(5):487-91. Disponible en: <http://www.nature.com/articles/5200219>

161. Li Y-Q, Zhang X-Y, Chen J, Yin J-Y, Li X-P. ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients . J Cancer Res Ther [Internet]. 2018;14(4):881. Disponible en: <http://www.cancerjournal.net/text.asp?2018/14/4/881/235102>
162. Alemany S, Vilor-Tejedor N, Bustamante M, Álvarez-Pedrerol M, Rivas I, Forns J, et al. Interaction between airborne copper exposure and ATP7B polymorphisms on inattentiveness in scholar children . Int J Hyg Environ Health [Internet]. 2017;220(1):51-6. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1438463916302577>
163. Squitti R, Ventriglia M, Gennarelli M, Colabufo NA, El Idrissi IG, Bucossi S, et al. Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimer's Disease: a Genetic Study of ATP7B Frequency . Mol Neurobiol [Internet]. 2017;54(1):671-81. Disponible en: <http://link.springer.com/10.1007/s12035-015-9664-6>
164. Aloisio M, Licastro D, Caenazzo L, Torboli V, D'eustacchio A, Severini GM, et al. A technical application of quantitative next generation sequencing for chimerism evaluation . Mol Med Rep [Internet]. 2016;14(4):2967-74. Disponible en: <https://www.spandidos-publications.com/10.3892/mmr.2016.5593>
165. Hua R, Hua F, Jiao Y, Pan Y, Yang X, Peng S, et al. Mutational analysis of ATP7B in Chinese Wilson disease patients . Am J Transl Res [Internet]. 2016;8(6):2851-61. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/27398169>
166. Li X-P, Yin J-Y, Wang Y, He H, Li X, Gong W-J, et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients . Tumor Biol [Internet]. 2014;35(8):8259-65. Disponible en: <http://link.springer.com/10.1007/s13277-014-2072-0>
167. Squitti R, Polimanti R, Bucossi S, Ventriglia M, Mariani S, Manfellotto D, et al. Linkage Disequilibrium and Haplotype Analysis of the ATP7B Gene in Alzheimer's Disease . Rejuvenation Res [Internet]. febrero de 2013;16(1):3-10. Disponible en: <https://www.liebertpub.com/doi/10.1089/rej.2012.1357>
168. Bucossi S, Polimanti R, Mariani S, Ventriglia M, Bonvicini C, Migliore S, et al. Association of K832R and R952K SNPs of Wilson's Disease Gene with Alzheimer's Disease . J Alzheimer's Dis [Internet]. 2012;29(4):913-9. Disponible en: <http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-2012-111997>
169. Wu Z-Y, Wang N, Lin M-T, Fang L, Murong S-X, Yu L. Mutation Analysis and the Correlation Between Genotype and Phenotype of Arg778Leu Mutation in Chinese Patients With Wilson Disease . Arch Neurol [Internet]. 2001;58(6):971. Disponible en: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur.58.6.971>
170. Squitti R, Ventriglia M, Gennarelli M, Colabufo NA, El Idrissi IG, Bucossi S, et al. Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimer's Disease: a Genetic Study of ATP7B Frequency. Mol Neurobiol [Internet]. 12 de

enero de 2017;54(1):671-81.

Disponible en:

<http://link.springer.com/10.1007/s12035-015-9664-6>

171. Lavrov A V., Chelysheva EY, Smirnikhina SA, Shukhov OA, Turkina AG, Adilgereeva EP, et al. Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia . BMC Genet [Internet]. 2016;17(S1):S14. Disponible en: <http://bmccgenet.biomedcentral.com/articles/10.1186/s12863-015-0308-7>

172. Tecza K, Pamula-Pilat J, Kolosza Z, Radlak N, Grzybowska E. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy . J Exp Clin Cancer Res [Internet]. 2015;34(1):2. Disponible en: <http://jccr.biomedcentral.com/articles/10.1186/s13046-015-0124-y>

173. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences . Nat Genet [Internet]. 1995;9(2):210-7. Disponible en: <http://www.nature.com/articles/ng0295-210>

174. Cox DW, Prat L, Walshe JM, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry . Hum Mutat [Internet]. 2005;26(3):280-280. Disponible en: <http://doi.wiley.com/10.1002/humu.9358>

175. Olsson C, Waldenström E, Westermarck K, Landegren U, Syvänen A-C. Determination of the frequencies of ten allelic variants of the Wilson disease gene (ATP7B), in pooled DNA samples . Eur J Hum Genet [Internet]. 2000;8(12):933-8. Disponible en: <http://www.nature.com/articles/5200566>

176. Figus A, Angius A, Loudianos G, Bertini C, Dessi V, Loi A, et al. Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations . Am J Hum Genet [Internet]. 1995;57(6):1318-24. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/1801406>

177. Tomić A, Dobričić V, Novaković I, Svetel M, Pekmezović T, Kresojević N, et al. Mutational analysis of ATP7B gene and the genotype-phenotype correlation in patients with Wilson's disease in Serbia . Vojnosanit Pregl [Internet]. 2013;70(5):457-62. Disponible en: <http://www.ncbi.nlm.nih.gov/pubmed/23789284>

178. Kucinkas L, Jeroch J, Vitkauskienė A, Sakalauskas R, Petrenkienė V, Kucinkas V, et al. High frequency of the c.3207C>A (p.H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease. World J Gastroenterol [Internet]. 2008;14(38):5876. Disponible en: <http://www.wjgnet.com/1007-9327/full/v14/i38/5876.htm>

179. Liu X-Q. Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease . World J Gastroenterol [Internet]. 2004;10(4):590. Disponible en: <http://www.wjgnet.com/1007-9327/full/v10/i4/590.htm>

180. Kumari N, Kumar A, Thapa BR, Modi M, Pal A, Prasad R. Characterization of mutation spectrum and identification of novel mutations in ATP7B gene from a cohort of Wilson disease patients: Functional and therapeutic implications . Hum Mutat [Internet]. 2018;39(12):1926-41. Disponible en: <http://doi.wiley.com/10.1002/humu.23614>

181. Leung M, Wu Lanzafame J, Medici V. Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations. *J Investig Med High Impact Case Reports* [Internet]. 10 de enero de 2020;8:232470961989687. Disponible en: <http://journals.sagepub.com/doi/10.1177/2324709619896876>
182. Jacquelet E, Beretti J, De-Tassigny A, Girardot-Tinant N, Wenisch E, Lachaux A, et al. L'observance dans la maladie de Wilson : intérêt d'un suivi rapproché au long cours. *La Rev Médecine Interne* [Internet]. marzo de 2018;39(3):155-60. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0248866317311827>
183. Gonzalez CP, Illera EF, Cárdenas CL, Jimenez EN, Mendez PG, Peralta VV, et al. Screening of Anxiety and Depression in Patients With Fibromyalgia From 18 to 65 Years Old and Its Relationship With the Severity of Fibromyalgia and Quality of Life. *Glob J Health Sci* [Internet]. 5 de noviembre de 2018;10(12):12. Disponible en: <http://www.ccsenet.org/journal/index.php/gjhs/article/view/0/37317>
184. Reales JM, Navarro-Jiménez E, Laborde-Cárdenas C, Gómez-Méndez P, Narvaez LCL. Implementation Plan of the Clinical Practice Guideline for the Early Detection, Diagnosis and Treatment of Patients With Alcohol Abuse or Dependence in a Colombian Hospital. *Glob J Health Sci* [Internet]. 11 de agosto de 2018;10(9):89. Disponible en: <http://www.ccsenet.org/journal/index.php/gjhs/article/view/76504>
185. Lucía, Rodríguez P, Óscar, Zurriaga Llorens MEGSC, Carbonell C. LA ENFERMEDAD DE WILSON: LAS DIVERSAS PERSPECTIVAS DEL PROFESIONAL SANITARIO, AFECTADO Y FAMILIAR. *Rev Esp Salud Publica* [Internet]. 2019;93(1). Disponible en: https://www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL93/O_BREVES/RS93C_201904014.pdf
186. Poujois A, Woimant F. Challenges in the diagnosis of Wilson disease. *Ann Transl Med* [Internet]. abril de 2019;7(S2):S67-S67. Disponible en: <http://atm.amegroups.com/article/view/24633/23691>
187. Valentino PL, Roberts EA, Beer S, Miloh T, Arnon R, Vittorio JM, et al. Management of Wilson Disease Diagnosed in Infancy. *J Pediatr Gastroenterol Nutr* [Internet]. enero de 2020;1. Disponible en: <http://journals.lww.com/10.1097/MPG.0000000000002608>
188. Navarro-Jimenez EI, Aroca Martínez G, Castillo LA, Gonzalez-Torres H. Membranoproliferative Glomerulonephritis C3 Deposits: Clinicopathological Study. *J Am Soc Nephrol*. 2015;
189. Castillo LA, Navarro-Jimenez EI, López I, Camacho K, Olivero M, Aroca Martínez G, et al. Membranoproliferative Glomerulonephritis C3 deposits: Clinicopathological Study. *Amercican J Nephrol* [Internet]. 2015;26(2015):459A. Disponible en: <https://www.asn-online.org/education/kidneyweek/archives/>
190. Navarro Jimenez E, Aroca Martínez G, Santos D. Implementación de un modelo de salud renal en red informática para la temprana detección y cuidado de la nefropatía primaria lúpica y glomerulonefritis en la Región Caribe

Colombiana. Rev Colomb Nefrol [Internet]. 2014;1. Disponible en: <http://www.revistanefrologia.org/index.php/rcn/article/view/145>

191. Castillo Parodi L, Navarro Jiménez E, Arango Quiroz Y, López Avendaño A, Mejía Varela V, González Torres HJ, et al. Obesity Association with Chronic Renal Disease in Patients attended at Clínica de la Costa. Barranquilla, Colombia. 2005-2014. Rev Colomb Nefrol [Internet]. 1 de enero de 2016;3(1):14-9. Disponible en: <http://www.revistanefrologia.org/index.php/rcn/article/view/217/pdf>

192. Poon K-S, Teo ZH, Yap JH, Koay ES, Tan K. Challenges in molecular diagnosis of Wilson disease: viewpoint from the clinical laboratory. J Clin Pathol [Internet]. 3 de diciembre de 2019;jclinpath-2019-206054. Disponible en: <http://jcp.bmj.com/lookup/doi/10.1136/jclinpath-2019-206054>

193. Zhu Q, Zhu K, Wang J, Bian W, Lu J. Relationship between genetic mutations and clinical phenotypes in patients with Wilson disease. Medicine (Baltimore) [Internet]. diciembre de 2019;98(49):e18284. Disponible en: <http://journals.lww.com/10.1097/MD.00000000000018284>

194. Jafari SH, Haseli S, Kaffashan S, Saeedi-Moghdam M, Iranpour P, Zeinali-Rafsanjani B. Assessment of the Hallmarks of Wilson Disease in CT Scan Imaging. J Med Imaging Radiat Sci [Internet]. diciembre de 2019; Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S1939865419305521>

195. Gawande A, Gupta GK, Gupta A, Wanjari SJ, Goel V, Rathore V, et al. Acute-on-Chronic Liver Failure: Etiology of Chronic and Acute Precipitating Factors and Their Effect on Mortality. J Clin Exp Hepatol [Internet]. noviembre de 2019;9(6):699-703. Disponible en: <https://linkinghub.elsevier.com/retrieve/pii/S0973688319301240>

196. Pinillos-Patiño Y, Herazo-Beltrán Y, Cataño JG, Ávila JR De. Actividad física y calidad de vida en personas con enfermedad renal crónica. Rev Med Chil [Internet]. 2019;147:153-60. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000200153